Is Natera (NTRA) Still Cheap, Or Is Cash Flow Doing The Heavy Lifting?

Detailed summary

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading.…

Natera has delivered very large share gains over the past three years, yet recent share price swings and shifting expectations now put the focus squarely on whether the current valuation lines up with the cash the business is expected to generate. With investors digesting new clinical data, Medicare decisions and a leadership change, the key issue is how much of that story is already reflected in the price.

The stock's next move may depend on whether the current share price is supported by the cash flows implied in the Discounted Cash Flow (DCF) based intrinsic value estimate.

To explore the same cash flow question that applies to Natera across a broader range of potential ideas, you can review a curated list of 32 high quality undervalued stocks

The Discounted Cash Flow (DCF) model here projects what Natera might return to shareholders through future free cash flows. Latest twelve month free cash flow sits at about $57.3 million, yet the forecast used in this DCF assumes that annual cash generation grows into the low single digit billions over the next decade, which is a big step up from today.

Such a steep ramp in projected free cash flow makes the output of the model very sensitive to how durable Signatera revenue proves to be, what it costs to keep scaling, and how much dilution or leverage is needed along the way. Because Medicare has expanded coverage for Signatera in hepatocellular carcinoma, the DCF currently points to an estimated intrinsic value substantially above the current share price of $322.94, implying the market is still applying a discount to those growth assumptions. Find out what Natera could be worth using our Discounted Cash Flow (DCF) estimate.

Natera's valuation puzzle only becomes clear once the underlying story is spelled out. This is where Simply Wall St Narratives on the Community page come in.

Bulls and bears looking at Natera are reading the same MRD and early detection story, yet they reach very different conclusions on what is already…

The…

Opening of the article, excerpted from Yahoo Finance. To read the rest, open the article on the publisher's site.